Human and viral whole genome sequencing identify HPV and APOBEC as oncogenic drivers in sinonasal squamous cell carcinoma

Harrison B. Chong[1,13]**, Michael E. Bryan**[2,3,4]**, Maoxuan Lin**[1,4]**, William C. Faquin**[5,6,7]**, Lisa Mirabello**[8]**, Sambit K. Mishra**[8,9]**, James S. Lewis Jr**[10,11,12]**, Michael Lawrence**[1,4,5]*****, Daniel Faden**[2,4,6,7]*¶**

[1] Krantz Family Center for Cancer Research, Massachusetts General Hospital, Charlestown, MA, United States
[2] Department of Otolaryngology-Head and Neck Surgery, Harvard Medical School, Boston, MA, United States
[3] Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
[4] Broad Institute of MIT and Harvard, Cambridge, MA, United States
[5] Department of Pathology, Massachusetts General Hospital, Boston, MA, United States
[6] Massachusetts General Hospital Cancer Center, Boston, MA, United States
[7] Massachusetts Eye and Ear, Boston, MA, United States
[8] Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD
[9] Cancer Genomics Research Laboratory, Leidos Biomedical Research, Inc., Frederick, MD, United States
[10] Department of Otolaryngology-Head and Neck Surgery, Vanderbilt University Medical Center, Nashville, TN, United States
[11] Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN, United States
[12] Department of Laboratory Medicine and Pathology, Mayo Clinic, Scottsdale, AZ, United States
[13] Children's Medical Center Research Institute, University of Texas Southwestern Medical Center, Dallas, TX, USA

Abstract

Sinonasal squamous cell carcinoma (SNSCC) is an aggressive head and neck cancer of the sinonasal cavity which has not benefitted from therapeutic advances over decades[1]. Though historically attributed to inhaled carcinogens such as hardwood dust and tobacco smoking[2], SNSCC is incidentally associated with human papillomavirus (HPV)[3,4]. Importantly, HPV is the primary oncogenic driver of >80% of anatomically adjacent oropharyngeal cancers[5]. While viral status drives clinical staging and treatment guidelines in these malignancies[6,7], the potentially oncogenic consequences and prognostic value of host–virus interactions in SNSCC remain incompletely defined. Here, through paired host and viral whole-genome sequencing (WGS), we map the genomic footprint of HPV in SNSCC. Strikingly, lesser studied strains such as HPV45, 51, and 39 constitute driver infections in this rare but clinically credentialed cancer, where extrachromosomal DNA (ecDNA)-associated viral integration and APOBEC mutagenesis are shown to underpin somatic tumor evolution.

Statement of Significance

Paired host viral and whole-genome sequencing of SNSCC nominates HPV as a primary oncogenic driver of SNSCC. HPV–human ecDNA amplicons harboring noncanonical strains such as HPV45, 51 mediate viral carcinogenesis. Routine clinical diagnostic HPV panels should be expanded to capture the activity of lesser studied strains.

Introduction

Our group and others have demonstrated that HPV is detectable in cancers in the nasopharynx and sinonasal tract[8,9], possibly due to refluxed secretions from the oropharynx. Notably, these cancers are rising both in incidence and within the same geographic locale as HPV+OPC[4]. Previous profiling suggests that HPV⁺ SNSCC shares mutational profiles with associated cervical and head and neck squamous cell carcinoma[10]. However, definitive genomic mapping of potentially oncogenic host-virus interactions through systematic sequencing of paired tumor-normal specimens remains under-explored. Here, we leverage

joint whole genome sequencing (WGS) of both human and HPV genomes to interrogate the

mutational signatures and structural events underpinning viral oncogenesis in SNSCC.

Results

Utilizing a cohort of 21 SNSCC paired tumor-normal specimens, we subjected each sample

to orthogonal tumor WGS (mean depth, 59x), matched normal WGS (mean depth, 30x), ultra-

deep WGS (10,000x) of the viral genome, and a broad HPV DNA PCR panel (see Methods,

Supplementary Table 11). Eighteen of 21 (86%) cases were HPV-associated by human WGS

and/or DNA PCR, with 94.4% concordance between the two technologies (Figure 1b; 17/18

jointly profiled; 95% CI, 74.2–99.0%; binomial p = <0.001, see Methods). Genotype

concordance was 81.0% (17/21; 95% CI, 60.0–92.3%; binomial p = 0.001). Sixteen of 21

(81%) were p16-positive (Figure 1c). Among patients reporting a smoking history, 7/14 (50%)

had ≥10 pack years (Figure 1c, Supplementary Table 12). Unlike HPV$^+$ OPC, where HPV16

predominates (~90%)[11,12], only 5/18 (27%) HPV+ SNSCC harbored single-genotype HPV16

(Supplementary Table 5). We observed nine distinct HPV genotypes (Figure 2a,

Supplementary Table 5), including two multi-genotype infections and two tumors with low-risk

HPV11 infection. Both low-risk (e.g. HPV11) infections and a plurality of high-risk genotypes

which vary in prevalence across human cancers (e.g. HPV16,18,35,39,45,51,56,59) were

present. Moreover, chimeric reads revealed an ecDNA species fusing viral DNA from HPV45,

a rare genotype in HPV$^+$OPC, to host DNA from the *TP63* oncogene (Figure 1d,

Supplementary Table 9), strongly suggesting an oncogenic role of less-common HPV

genotypes in SNSCC. Interestingly, a broad representation of high-risk HPV genotypes other

than HPV16 has also been observed in nasopharyngeal cancer, an oropharynx-adjacent site

where HPV appears to play a role[13]. One HPV11$^+$ tumor lacked any high-risk genotype and

showed no evidence of viral integration but harboured a TP53 mutation and was p16-negative,

consistent with HPV11 as a bystander in this case[14] (Supplemental Tables 1-2, 11).

Somatic retro-integration of all or part of the HPV genome is a well-described carcinogenic

mechanism in HPV[+] OPC, as well as cervical and anal cancers[15,16]. We identified high-

confidence integration breakpoints in most HPV[+] tumors, with as many as 7 distinct

breakpoints per tumor. In total, 28 unique, high evidence viral-host junctions were mapped

(Figure 2b, Supplemental Tables 5-9). In cases harboring multi-genotype infections, only a

single dominant integrating genotype was observed per tumor, suggesting that one genotype

primarily drives oncogenic progression, even amid co-infection by other HPV types. This

observation is consistent with findings in cervical and anal cancers[17,18].

Our cohort also exhibited novel patterns of HPV integration (Figure 2c,d). In several cases,

integration was accompanied by profound local copy-number amplification of host and viral

sequences, including a retro-integration event involving the 3′ region of TP63 in an HPV45[+]

tumor (Figure 2d, top). Focal segmentation of the somatic breakpoints delimiting this fusion

revealed a ~50kb segment of chromosome 3q which achieved amplification to ~15–20X

genomic median (i.e. "copies"). This segment included the HPV45 E6 URR sequences fused

to TP63. The structure and amplitude of this amplicon resemble oncoviral integration-linked

extrachromosomal DNA (ecDNA)[19,20] (Figure 2d, top). To our knowledge, this is the first

demonstration of an HPV ecDNA-like amplification in SNSCC.

We further observed amplification in a tumor with HPV51 with three distinct HPV51

breakpoints clustered at the 3′ end of MAN1A2. Each breakpoint was associated with a distinct

copy-number profile, but all showed high-level amplification (~15–50 copies). This suggests

either sequential chromosomal rearrangements or the presence of multiple "nested" ecDNA

species containing segments of HPV51 and MAN1A2 (Figure 2d, bottom). Initial integration

may have been followed by stepwise extrusion of some segments via iterative breakage-fusion

cycles. Yet, not all HPV integrations cause detectable copy-number changes. For instance,

one tumor showed history of HPV18 integration into the 3' end of N4BP3 without associated

copy gain or loss (Figure 2d, middle).

We next interrogated the host somatic mutational landscape. The overall mutation burden was

comparable to that reported in HPV+OPC[21], and clonal mutations were observed in common

driver genes regulating mitogenic signaling and genomic integrity (e.g. *PIK3CA, KDM6A,*

MLL3, BCOR, CHEK2) (Figure 1c, g; Supplemental Tables 1,2). Among high-risk HPV+ cases,

4/17 (23%) harbored *PIK3CA* missense mutations (Figure 1e). Three of these were in the

helical domain, a hotspot enriched for APOBEC3-mediated mutations[22]. *TP53* and *CDKN2A*

mutations were mutually exclusive with high-risk HPV infection, whereas *PIK3CA* mutations

were seen only in high-risk HPV+ cases. These observations are consistent with reports of

depletion of *TP53/CDKN2A* mutation in HPV+OPC, as well as enrichment of mutations in the

PIK3CA helical domain[23]. FGFR3 S249C mutations, recently noted in SNSCC[10], were not

detected in this cohort. Genome-wide, SNSCCs exhibited a mutational rate like that of

previously profiled HPV-independent head and neck squamous cell carcinoma (HPV- HNSCC)

(Extended Data Fig. 2a). Despite reasonable sequencing depth and tumor purity, we did not

recover any confidently-called somatic mutations in the tumors of two patients (tumor purity

MS09 = 0.64, 21530 = 0.46).

Knowing that APOBEC mutagenesis is a primary driver in HPV-associated carcinomas[24], we

interrogated mutational signatures in both host and viral genomes. Factorization of somatic

mutations identified predominant APOBEC mutagenesis in a subset of SNSCC (Figure 1e).

We observed low burden of the smoking-related signature SBS4 in patients with a history of

smoking[25,26], arguing against smoking as a primary etiology of SNSCC[27]. When projected

alongside TCGA HNSCC, SNSCC showed a greater diversity of APOBEC3 activity and a

similar overall mutational burden (Extended Data Fig. 2c, 2d). HPV+ SNSCC appears to have

less APOBEC3 mutagenesis on average than its less histologically specialized counterpart

(HPV+ HNSC), but 2/21 (9%) of HPV+ SNSCC tumors ranked among the most enriched

APOBEC-mutators in the TCGA-ICGC combined cohort (Extended Data Fig. 2b, left;

Extended Data Fig. 2c, bottom).

Ultra-deep sequencing of intratumoral HPV genomes showed that APOBEC activity extends

to the virus (Figure 2E, Supplementary Tables 6-7). Highly clonal virus mutations likely

represent mutations present in the infecting virion; however, a small peak of lower allele

frequency subclonal mutations in some instances represents new APOBEC-associated

mutations that occurred in the current host (Figure 2e, f). Specifically, we detected the

contribution of clonal APOBEC mutagenesis near the L1 domain in a subset of HPV genomes,

corroborating ongoing APOBEC3 activity throughout the viral genome in tumors (Figure 2e, f).

Concordance of host–virus APOBEC mutagenesis has to our knowledge not previously been

demonstrated as a principle in SNSCC[28,29].

Knowing that structural variants (SVs) are well-represented in HNSCC[30], we next asked

whether this principle extends to SNSCC (Extended Data Fig. 2a, Supplementary Tables 3,

10). We identified 221 somatic SVs, with an average of ~10 SVs per tumor. Consistent with

patterns reported in other cancers[30], simple deletions were the most common class of SV. We

observed focal deletions affecting known tumor suppressor loci – for example, loss of PTEN

was recurrent in multiple tumors (Extended Data Fig. 2b), suggesting that PTEN inactivation

may play a role in some SNSCCs. Moreover, PTEN loss is also seen in a subset of HPV[+] OPC

and could contribute to PI3K/AKT activation[31].

SVs targeting genes were common, where 41% of SVs localized to introns, exons, or other

gene-regulatory elements (i.e. promoters), sometimes creating chimeric, in-frame fusion

transcripts with epigenetic regulators such as NIPBL or BRWD1 (Extended Data Fig. 2c,e).

We also identified chromosomal catastrophe in specific tumors. In one HPV[+] SNSCC, copy-

number oscillations and clustered breakpoints along a single chromosome arm characteristic

of chromothripsis were detected, notably producing an in-frame ERG-BRWD1 fusion

product[32]. Analysis of whole chromosomes also identified kataegis in a separate case[33]

(Extended Data Fig. 2d, e). This suggests that as double-strand breaks were salvaged,

APOBEC might have been concurrently active, peppering exposed single-stranded DNA with

C→T mutations. Additionally, a few tumors with otherwise low mutation burden demonstrated

chromoplexy-like rearrangements, i.e. showers of interrelated intrachromosomal SVs

(Extended Data Fig. 2e).

Discussion

In summary, HPV drives tumorigenesis in SNSCC, and in a subset of cases, the mutagenic

activities of the APOBEC3 family of anti-viral DNA cytosine deaminases further accelerates

tumor evolution. Moreover, viral WGS directly evidences APOBEC targeting to the viral

genome. Viral integration events, particularly the extrachromosomal amplification of known

oncogenes such as *TP63*, as well as genomic breakpoints and translocations, contribute to

extensive structural variation. These structural variations collectively demonstrate the

cooperative roles of both viral and non-viral axes of instability in tumor evolution. The diversity

of HPV genotypes other than HPV16 provides a striking contrast to HPV+ OPC, suggesting

less evolutionary advantage for HPV16 outside of the oropharynx. Importantly, nontraditional,

high-risk HPV genotypes play an underrecognized role in SNSCC, pinpointing a need for

diagnostic inclusion in routine clinical assays.

METHODS DETAILS

Patient Cohort and Sample Collection

Primary tumor and matched normal blood samples were collected from 21 patients diagnosed

with sinonasal squamous cell carcinoma (SNSCC)[52]. Of these, 16 were from Mass General

Brigham and 5 were from Vanderbilt University Medical Center. All patients provided written

informed consent under protocols approved by both institutions. Clinicopathological features,

including age, sex, smoking history, anatomical subsite, histologic subtype (keratinizing vs.

non-keratinizing), and inverted papilloma association, were extracted from medical records. In

addition to standard clinical assays (p16 immunohistochemistry and HPV PCR), all patients

underwent gold-standard HPV genotyping performed at the U.S. National Institutes of Health

(NIH). HPV detection and typing were performed using the TypeSeq v1 and NCI Carcinogenic

HPV All Next Generation Sequencing (NCI CHANGeS) assays. TypeSeq v1 detects 51 HPV

genotypes, while NCI CHANGeS provides high-resolution genotyping of 12 high-risk types

(HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59).[52]

WGS

DNA was extracted from the tumor and blood using the [Qiagen DNeasy Blood & Tissue Kit]

according to the manufacturer's protocol. DNA quality and quantity were assessed with [Qubit

fluorometry / TapeStation]. Libraries for whole-genome sequencing (WGS) were prepared

using the Illumina TruSeq DNA PCR-Free Library Prep Kit. Paired-end sequencing (151 bp)

was performed on an Illumina platform to an average depth of ~59x for tumor DNA and ~30x

for matched normal DNA. Raw reads were trimmed to remove adaptors and low-quality bases

with TrimGalore (v0.6.6, a wrapper of the Cutadapt program[34]. Reads were aligned to a hybrid

human-HPV reference composed of human genome (GRCh37/hg19) and all HPV genomes

downloaded from PaVE[35] using BWA-MEM[36] (v0.7.15) with default settings. Sorted, indexed

BAM files were generated with SAMtools[37] (v1.4.1). PCR duplicates were marked with

Sambamba[38] (v0.4.7).

HPV DNA was captured using a custom Ion AmpliSeq panel with 545 primer pairs, covering

overlapping amplicons across the 12 high-risk HPV types considered in this study. The

barcoded libraries were prepared using Ion AmpliSeq Library Kit 2.0 (Thermo Fisher Scientific,

Carlsbad, CA). Primers were divided into two separate PCR reactions to avoid cross-reaction

and primer dimerization. Amplicon lengths ranged from 69 bp to 324 bp, with a median length

of 199 bp. Whole-genome single-end sequencing was performed for all 12 HR-HPV types

concurrently on the Ion PGM platform. Raw reads were trimmed to remove adaptors and low-

quality bases with TrimGalore (v0.6.10; a wrapper of the Cutadapt program[34]. Reads were

aligned to the hybrid human-HPV reference using BWA-MEM[35] (v0.7.18) with default settings.

Sorted, indexed BAM files were generated with SAMtools[36] (v1.21). PCR duplicates were

removed with Picard (v3.3.0; "Picard Toolkit." 2019. Broad Institute, GitHub Repository.

https://broadinstitute.github.io/picard/; Broad Institute). HPV mutations were called using

Mutect1[39] (v1.1.7) in unpaired mode using the hybrid human-HPV reference described

previously. Low quality mutations with number of alternate alleles <2 and total number of reads

< 20 were removed. The remaining mutations were manually reviewed with the Integrative

Genomics Viewer[40] (IGV, v2.18.4) to exclude false positives. HPV APOBEC mutations were

annotated into three categories: 1) high-confidence APOBEC mutations Tp(C->G/A)pN, 2)

medium-confidence APOBEC mutations Tp(C->T)pH, and 3) low-confidence APOBEC

mutations Tp(C->T)pG.

Mutation calling

Somatic single-nucleotide variants (SNVs) and small insertions and deletions (indels) were

called using MuTect1[39] (v1.1.7) and Strelka2[41] (v2.9.10) using matched tumor/normal pairs.

Low quality variants were first removed with progressively stricter filtering thresholds

combining Panel of Normal (PoN) and minimum counts of alternate alleles in tumors

(t_alt_count) for variants in different ranges of tumor allele fractions (AF): 1) for mutations with

1%<=AF < 2%, PoN <0.05% and t_alt_count >=5, 2) for mutations with 2% <=AF<3%, PoN <

0.1% and t_alt_count >=4, 3) for mutations with 3% <=AF<5%, PoN < 0.15% and t_alt_count

>=3, and 4) for mutations with AF>=5%, PoN < 0.2% and t_alt_count >=2, in addition to a total

read count of five in tumor, were applied. To remove FFPE artifacts in the remaining mutations,

a combination of three tools: FiNGs[42] with default filters of the International Cancer Genome

Consortium (ICGC), SOBDetector[43], and a perl tool that detects false positives with biased

read diversity[44]. High-confidence variants were functionally annotated with ANNOVAR[45].

Coding variants with allele fraction > 10% in known driver genes and all coding indels were

manually reviewed with the Integrative Genomics Viewer[40] (IGV, v2.18.4) to exclude false

positives.

Mutational signature attribution

Non-negative matrix factorization (NMF) was applied to pooled samples from our cohort and The Cancer Gene Atlas (TCGA) to decompose mutations into respective single base substitution signatures. Loadings of dominant signatures with acceptable cosine similarity >= 0.85 were projected onto a three-dimensional manifold via the umap.UMAP function in the umap.umap_ Python package (n_neighbors=15, random_state=42, n_components=3).

Identification of structural variants and copy number alterations

Somatic SVs were identified using dRanger and BreakPointer as described previously[46]. Copy number segments were obtained via FACETS and subsequently fed into GISTIC analysis via the Broad pipeline. All HPV genomes were passed through SvABA for human-viral breakpoint detection[51], followed subsequently by manual review for high evidence (read lattering, sufficient read depth) of chimeric reads suggestive of human-HPV breakpoints.

ecDNA detection

Extrachromosomal DNA (ecDNA) amplifications were detected using Amplicon-pipeline[47] v1.3.9. Briefly, focal DNA copy-number variants (CNV) were first identified using CNVKit[48] v0.9.12 . Regions with copy number >=4.5 and size >50kbp were selected as seed regions. These seed regions were then passed to AmpliconArchitect v1.5.r2 to construct cyclic paths, and AmpliconClassifier v1.3.3 was used to determine whether these paths were likely to be ecDNA[47,49]. ecDNA candidates were manually reviewed with the Integrative Genomics Viewer[40] (IGV, v2.18.4) to identify real ecDNA amplifications.

References

1. Consonni, D. *et al.* Survival of Patients with Sinonasal Cancers in a Population-Based Registry, Lombardy, Italy, 2008-2023. *Cancers* **16**, 896 (2024).

2. Fukuda, K. & Shibata, A. Exposure-response relationships between woodworking, smoking or passive smoking, and squamous cell neoplasms of the maxillary sinus. *Cancer Causes Control CCC* **1**, 165–168 (1990).

3. Oliver, J. R. *et al.* Human papillomavirus and survival of patients with sinonasal squamous cell carcinoma. *Cancer* **126**, 1413–1423 (2020).

4. Chang Sing Pang, K. J. W., Mur, T., Collins, L., Rao, S. R. & Faden, D. L. Human Papillomavirus in Sinonasal Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis. *Cancers* **13**, 45 (2020).

5. D'Souza, G. *et al.* Differences in the Prevalence of Human Papillomavirus (HPV) in Head and Neck Squamous Cell Cancers by Sex, Race, Anatomic Tumor Site, and HPV Detection Method. *JAMA Oncol.* **3**, 169–177 (2017).

6. Ang, K. K. *et al.* Human papillomavirus and survival of patients with oropharyngeal cancer. *N. Engl. J. Med.* **363**, 24–35 (2010).

7. Fakhry, C. *et al.* Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. *J. Natl. Cancer Inst.* **100**, 261–269 (2008).

8. Hung, S.-H., Yang, T.-H., Cheng, Y.-F., Chen, C.-S. & Lin, H.-C. Association of Nasopharynx Cancer with Human Papillomavirus Infections. *Cancers* **15**, 4082 (2023).

9. Bryan, M. E. *et al.* Direct Comparison of Alternative Blood-Based Approaches for Early Detection and Diagnosis of HPV-Associated Head and Neck Cancers. *Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res.* OF1–OF11 (2025) doi:10.1158/1078-0432.CCR-24-2525.

10. Zamuner, F. T. *et al.* Molecular patterns and mechanisms of tumorigenesis in HPV-associated and HPV-independent sinonasal squamous cell carcinoma. *Nat. Commun.* **16**, 5285 (2025).

11. Gillison, M. L., Chaturvedi, A. K., Anderson, W. F. & Fakhry, C. Epidemiology of Human Papillomavirus–Positive Head and Neck Squamous Cell Carcinoma. *J. Clin. Oncol.* **33**, 3235–3242 (2015).

12.   Nichols, A. C. *et al.* Does HPV type affect outcome in oropharyngeal cancer? *J.*

Otolaryngol. - Head Neck Surg. J. Oto-Rhino-Laryngol. Chir. Cervico-Faciale **42**, 9 (2013).

13.   Zhao, B. Y., Hirayama, S., Goss, D., Zhao, Y. & Faden, D. L. Human papillomavirus-

associated nasopharyngeal carcinoma: A systematic review and meta-analysis. *Oral*

Oncol. **159**, 107057 (2024).

14.   Muñoz, N. *et al.* Epidemiologic classification of human papillomavirus types

associated with cervical cancer. *N. Engl. J. Med.* **348**, 518–527 (2003).

15.   Pinatti, L. M., Walline, H. M. & Carey, T. E. Human Papillomavirus Genome

Integration and Head and Neck Cancer. *J. Dent. Res.* **97**, 691–700 (2018).

16.   Zhang, Y., Qiu, K., Ren, J., Zhao, Y. & Cheng, P. Roles of human papillomavirus in

cancers: oncogenic mechanisms and clinical use. *Signal Transduct. Target. Ther.* **10**, 44

(2025).

17.   Schmitt, M. *et al.* Abundance of multiple high-risk human papillomavirus (HPV)

infections found in cervical cells analyzed by use of an ultrasensitive HPV genotyping

assay. *J. Clin. Microbiol.* **48**, 143–149 (2010).

18.   Wong, A. K. *et al.* Human papillomavirus genotypes in anal intraepithelial neoplasia

and anal carcinoma as detected in tissue biopsies. *Mod. Pathol. Off. J. U. S. Can. Acad.*

Pathol. Inc **23**, 144–150 (2010).

19.   Bafna, V. & Mischel, P. S. Extrachromosomal DNA in Cancer. *Annu. Rev. Genomics*

Hum. Genet. **23**, 29–52 (2022).

20.   McBride, A. A. & White, E. A. HPV Integration Can Drive the Formation of Virus-Host

Extrachromosomal DNA in Tumors. *Cancer Discov.* **13**, 814–816 (2023).

21.   Lim, Y. X., Mierzwa, M. L., Sartor, M. A. & D'Silva, N. J. Clinical, morphologic and

molecular heterogeneity of HPV-associated oropharyngeal cancer. *Oncogene* **42**, 2939–

2955 (2023).

22.   Henderson, S., Chakravarthy, A., Su, X., Boshoff, C. & Fenton, T. R. APOBEC-

mediated cytosine deamination links PIK3CA helical domain mutations to human

papillomavirus-driven tumor development. *Cell Rep.* **7**, 1833–1841 (2014).

23. Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. *Nature* **517**, 576–582 (2015).

24. Argyris, P. P. *et al.* Endogenous APOBEC3B overexpression characterizes HPV-positive and HPV-negative oral epithelial dysplasias and head and neck cancers. *Mod. Pathol. Off. J. U. S. Can. Acad. Pathol. Inc* **34**, 280–290 (2021).

25. Alexandrov, L. B. *et al.* The repertoire of mutational signatures in human cancer. *Nature* **578**, 94–101 (2020).

26. Wellcome Sanger Institute. *Mutational Signatures (v3.4 - October 2023) SBS4 GRCh37 COSMIC V102*. https://cancer.sanger.ac.uk/signatures/sbs/sbs4/ (2023).

27. Elgart, K. & Faden, D. L. Sinonasal Squamous Cell Carcinoma: Etiology, Pathogenesis, and the Role of Human Papilloma Virus. *Curr. Otorhinolaryngol. Rep.* **8**, 111–119 (2020).

28. Faden, D. L. *et al.* APOBEC Mutagenesis Is Concordant between Tumor and Viral Genomes in HPV-Positive Head and Neck Squamous Cell Carcinoma. *Viruses* **13**, 1666 (2021).

29. Vartanian, J.-P., Guétard, D., Henry, M. & Wain-Hobson, S. Evidence for editing of human papillomavirus DNA by APOBEC3 in benign and precancerous lesions. *Science* **320**, 230–233 (2008).

30. Sasa, N. *et al.* Intratumor heterogeneity of HPV integration in HPV-associated head and neck cancer. *Nat. Commun.* **16**, 1052 (2025).

31. Chiosea, S. I. *et al.* PIK3CA, HRAS and PTEN in human papillomavirus positive oropharyngeal squamous cell carcinoma. *BMC Cancer* **13**, 602 (2013).

32. Stephens, P. J. *et al.* Massive genomic rearrangement acquired in a single catastrophic event during cancer development. *Cell* **144**, 27–40 (2011).

33. Nik-Zainal, S. *et al.* Mutational processes molding the genomes of 21 breast cancers. *Cell* **149**, 979–993 (2012).

34. Martin, M. (2011). Cutadapt removes adapter sequences from high-throughput sequencing reads. *EMBnet. journal*, *17*(1), 10-12.

35.   Van Doorslaer, K., Li, Z., Xirasagar, S., Maes, P., Kaminsky, D., Liou, D., ... & McBride, A. A. (2017). The Papillomavirus Episteme: a major update to the papillomavirus sequence database. *Nucleic acids research*, *45*(D1), D499-D506.

36.   Li, H. (2013). Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. *arXiv preprint arXiv:1303.3997*.

37.   Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., ... & 1000 Genome Project Data Processing Subgroup. (2009). The sequence alignment/map format and SAMtools. *bioinformatics*, *25*(16), 2078-2079.

38.   Tarasov, A., Vilella, A. J., Cuppen, E., Nijman, I. J., & Prins, P. (2015). Sambamba: fast processing of NGS alignment formats. *Bioinformatics*, *31*(12), 2032-2034.

39.   Cibulskis, K., Lawrence, M. S., Carter, S. L., Sivachenko, A., Jaffe, D., Sougnez, C., ... & Getz, G. (2013). Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. *Nature biotechnology*, *31*(3), 213-219.

40.   Robinson, J. T., Thorvaldsdóttir, H., Winckler, W., Guttman, M., Lander, E. S., Getz, G., & Mesirov, J. P. (2011). Integrative genomics viewer. *Nature biotechnology*, *29*(1), 24-26.

41.   Kim, S., Scheffler, K., Halpern, A. L., Bekritsky, M. A., Noh, E., Källberg, M., ... & Saunders, C. T. (2018). Strelka2: fast and accurate calling of germline and somatic variants. *Nature methods*, *15*(8), 591-594.

42.   Wardell, C. P., Ashby, C., & Bauer, M. A. (2021). FiNGS: high quality somatic mutations using filters for next generation sequencing. *BMC bioinformatics*, *22*(1), 77.

43.   Diossy, M., Sztupinszki, Z., Krzystanek, M., Borcsok, J., Eklund, A. C., Csabai, I., ... & Szallasi, Z. (2021). Strand Orientation Bias Detector to determine the probability of FFPE sequencing artifacts. *Briefings in Bioinformatics*, *22*(6).

44.   Yost, S. E., Smith, E. N., Schwab, R. B., Bao, L., Jung, H., Wang, X., ... & Frazer, K. A. (2012). Identification of high-confidence somatic mutations in whole genome sequence of formalin-fixed breast cancer specimens. *Nucleic acids research*, *40*(14), e107-e107.

45.   Wang, K., Li, M., & Hakonarson, H. (2010). ANNOVAR: functional annotation of

genetic variants from high-throughput sequencing data. *Nucleic acids research*, *38*(16),

e164-e164.

46.   Isozaki, H., Sakhtemani, R., Abbasi, A., Nikpour, N., Stanzione, M., Oh, S., ... &

Hata, A. N. (2023). Therapy-induced APOBEC3A drives evolution of persistent cancer

cells. *Nature*, *620*(7973), 393-401.

47.   Luebeck, J., Huang, E., Kim, F., Liefeld, T., Dameracharla, B., Ahuja, R., ... & Bafna,

V. (2024). AmpliconSuite: an end-to-end workflow for analyzing focal amplifications in cancer

genomes. *bioRxiv*, 2024-05.

48.   Talevich, E., Shain, A. H., Botton, T., & Bastian, B. C. (2016). CNVkit: genome-wide

copy number detection and visualization from targeted DNA sequencing. *PLoS*

computational biology, *12*(4), e1004873.

49.   Deshpande, V., Luebeck, J., Nguyen, N. P. D., Bakhtiari, M., Turner, K. M., Schwab,

R., ... & Bafna, V. (2019). Exploring the landscape of focal amplifications in cancer using

AmpliconArchitect. *Nature communications*, *10*(1), 392.

50.   Ashkenazy, H., Abadi, S., Martz, E., Chay, O., Mayrose, I., Pupko, T., & Ben-Tal, N.

(2016). ConSurf 2016: an improved methodology to estimate and visualize evolutionary

conservation in macromolecules. *Nucleic acids research*, *44*(W1), W344-W350.

51.   Wala, J. A., Bandopadhayay, P., Greenwald, N. F., O'Rourke, R., Sharpe, T.,

Stewart, C., ... & Beroukhim, R. (2018). SvABA: genome-wide detection of structural variants

and indels by local assembly. *Genome research*, *28*(4), 581-591.

52.   Wagner, S., Roberson, D., Boland, J., Kreimer, A. R., Yeager, M., Cullen, M., ... &

Wentzensen, N. (2019). Evaluation of TypeSeq, a novel high-throughput, low-cost, next-

generation sequencing-based assay for detection of 51 human papillomavirus

genotypes. *The Journal of infectious diseases*, *220*(10), 1609-1619.

 Figure Legends

 Figure 1. **A portrait of genomic aberrations in SNSCC** (a) Previous studies utilizing different

modalities (PCR, p16 stain, ISH, etc.) report varying rates of HPV positivity in SNSCC[4]. (b)

HPV positivity rate as detected in the current study (21 SNSCC), by WGS. (c) Focal

segmentation of HPV-encoding extrachromosomal DNA hijacking the *TP63* oncogene,

resulting in local copy number gain as estimated by Amplicon Architect[47]. A semi-circular arc

connecting two loci denotes chimeric reads which map to two sites. (d) Clinical phenotypes

and histopathological traits present in a cohort of 21 patients with SNSCC. (e) Decomposition

of somatic mutations in individual patients into corresponding mutational signatures (left, see

Methods). Oncoplot summarizing the genomic landscape of 21 SNSCCs, including: tumor

ploidy, overall mutational burden, HPV genotype by WGS, and the relative contribution of

different single base substitution signatures (right). Select examples of patients which are

enriched for different SBS signatures (e.g. Patient 12 APOBEC, Patient 15 UV Sig7b) are

shown. (f) Assessment of point mutations in known cancer driver genes, highlighting examples

of *PIK3CA* mutations which are recurrent in HPV+ cancers as well as TCGA HNSCC,

overlaying protein-relative residue-level conservation in PIK3CA.[50] Cartoon visualizes the

localization of individual *PIK3CA* mutations among four SNSCC profiled herein (Patients 12,

47180, 52087, 4139). (g) Evaluation of candidate somatic driver genes in SNSCC by

assessment of mutational clonality (left), highlighting evidence of clonal mutations in known

driver genes (*CHEK2, KDM6A*) in two different patients (right).

Figure 2. **Genomic record of HPV activity in SNSCC** (a) Sequencing coverage of individual

HPV genomes which were detected across 21 SNSCC. (b) Linearized representation of the

approximate location of viral genes in the HPV genome (top). Distribution of HPV positivity

(total number of genotypes per patient) and detectable hg19-HPV breakpoints among HPV[+]

patients (bottom). (c) Circos plot mapping the somatic integration of HPV into the human

genome, sub-stratified by HPV genotype and highlighting the identification of a chimeric *TP63-*

HPV45 amplicon. Each arc represents chimeric reads mapping across two sites (d) High-

resolution characterization of select HPV integration sites in 3 SNSCC patients. Co-option of the *TP63* oncogene into an HPV45-containing amplicon (top). Evidence of subclonal integration of HPV18 (3' UTR of *N4BP3*) without corresponding copy number instability in the human genome (middle). Focal copy number gain (50X genomic median) of *MAN1A2*-HPV51 amplicon (bottom). (e) Clonality of mutations across the HPV genome as detected by viral WGS, highlighting the contribution of APOBEC mutagenesis. (f) Distribution of mutational clonality within the HPV genome (left), and distribution of mutations across the HPV genome, highlighting targeted domains (right).

Figure S1. **Pan-cancer context of mutational signature activity in SNSCC** (a) Scatter-plot depicting the genomic mutational rates of different TCGA-ICGC cancer lineages, highlighting SNSCC. (b) Cartography of mutational signatures across human cancers, highlighting the distribution of SNSCC relative to TCGA HNSCC. UMAP loadings of seven prominent SBS signatures (BRCA, APOBEC, Aging, UV Sig7b, A$\rightarrow$G Sig 12, Smoking) are used to partition individual TCGA-ICGC tumors along different mutational "trajectories." Each dot in the cartography represents a single tumor and is colored by the dominant mutational signature. Select cancer subtypes (e.g. HPV$^+$ HNSCC) are highlighted with symbols. The mutational signatures of two select patients which are profoundly enriched for different signatures at the single base level (top left Patient 47180, APOBEC-enriched; bottom right 64208, UV-enriched) are deconvolved into corresponding histograms and lego plots to highlight the mutational content of each signature. (c) Top, scatter plot directly compares the total mutational burden in HPV$^+$ SNSCC to HPV$^-$ HNSCC, HPV$^+$ HNSCC, and HPV$^+$ CESC. Bottom, scatter plot directly compares APOBEC signature loadings among different HNSCC subtypes, highlighting select SNSCC which are both HPV$^+$ and APOBEC-enriched. p-values were computed using the MATLAB ttest2() function. (d) Explicit plotting of SNSCC and TCGA-ICGC genomes into SBS signatures, sorted by APOBEC loading.

Figure S2. **Discovery of structural variants in SNSCC** (a) Abundance of SVs of various classes in 21 SNSCC (left). Size distributions of deletions (right). (b) GISTIC (Genomic Identification of Significant Targets in Cancer, Broad pipeline) output showing common focal copy number alterations present among 21 SNSCC, highlighting regions of focal PTEN copy number loss across three patients. (c) Whole genome circos plot defining the constellation of different classes of inter- and intra-chromosomal SVs which are harbored across 21 SNSCC. Detection of an in-frame fusion between exon 24 of NIPBL and exon 10 of DNAJC21 in a single patient, showcasing raw densities of both chimeric and wildtype reads at the mapped genomic breakpoints in both tumor and normal samples (top left). (d) Detection of kataegic storms of APOBEC-related mutations on chromosome 12 of patient 12. Radial scatter plot depicts the inter-mutational distances between mutations. (e) Tracing of structural variations to allelic and copy number imbalance in patient 8 across whole chromosomes (17, 18, 19, 20, 21). Clustered targeting of intra-chromosomal rearrangements resulting in loss of chromosome 21; focal gain on chromosome 17; oscillating copy number states on chromosome 19; as well as a chromothriptic shower of intra-chromosome 21 rearrangements, leading to an in-frame fusion between ERG and BRWD1, are highlighted.

Figure 1

Figure 2

Figure S1

Figure S2